Amarillo Biosciences (AMAR.OB) to Unveil New HIV Medicine
Amarillo Biosciences (OTCBB: AMAR) made waves yesterday when it announced that two new clinical sites - one in New Jersey and one in Pennsylvania - would be ready to enroll new patients in a Phase 2 study on "a test of low-dose interferon alpha lozenges administered orally to HIV-positive subjects with oral warts."While it may sound like a disgusting and trivial waste of manpower, the company's Phase 2 tests are actually quite necessary. Viral lesions found in the mouths of HIV patients are common, painful, and are indicative of disease progression. According to the company's press release, one of the…